FIRALIS MOLECULAR PRECISION SA

Their core work

Firalis is a French biotech SME specializing in molecular biomarker discovery and in-vitro diagnostic (IVD) assay development for complex diseases. They translate biological signatures — particularly RNA-based biomarkers — into clinically validated tests that predict treatment response and patient outcomes. Their work sits at the intersection of precision medicine, companion diagnostics, and AI-driven prediction modeling. In practice, they help pharma and clinical partners decide who will respond to a therapy before it is given.

What they specialise in

How they've shifted over time

Between 2015 and 2018 Firalis focused on immunology and autoimmune disease, specifically validating a biomarker panel for rheumatoid arthritis treatment response. From 2020 onward their attention shifted toward cardiovascular and infectious-disease diagnostics, with long non-coding RNA and AI-driven prediction models becoming central. The trajectory shows a clear move from single-disease clinical validation toward multi-indication, RNA-based precision diagnostics.

They are moving toward AI-enabled, RNA-based prognostic diagnostics with applications across cardiology and infectious disease — a promising partner for precision-medicine and companion-diagnostic consortia.

How they like to work

Firalis is comfortable leading — they coordinated a EUR 4.99M SME-Instrument project — and also willing to enter large consortia as a third-party technical contributor, as in COVIRNA. Across just two projects they already worked with 15 partners in 12 countries, suggesting they assemble or plug into broad European clinical networks rather than repeating the same small team. Expect a partner that can either drive a clinical-validation workpackage or slot in as the IVD specialist.

Connected to 15 unique partners across 12 countries in only two projects, indicating a wide, pan-European clinical and research network rather than a local cluster.

What sets them apart

Unlike generic diagnostic SMEs, Firalis combines proprietary RNA biomarker discovery with full clinical-validation capability and regulatory-grade IVD development — a rare end-to-end chain in a single mid-size company. They have already secured a flagship SME-Instrument coordinator grant, which signals both technical readiness and managerial capacity. Partners get a biotech that can take a biomarker hypothesis all the way to a CE-marked test.

Highlights from their portfolio

• RABIOPRED
  Coordinator role with nearly EUR 5M EC funding to clinically validate a rheumatoid arthritis treatment-response biomarker — their flagship demonstration of end-to-end IVD development.
• COVIRNA
  Unusual crossover of long non-coding RNA, cardiovascular biomarkers and AI applied to COVID-19 prognosis — shows their pivot into RNA-based precision diagnostics.